Bridging With Chimeric Antigen Receptor T‐Cell Therapy or Chemotherapy to Allo‐ <scp>HSCT</scp> in B‐ <scp>ALL</scp> : A Comparison of Treatment Complications and Survival
Our data indicate that, in B-ALL patients, most treatment-related complications and survival were comparable between CAR T-cell therapy and chemotherapy followed by allo-HSCT.
Authors
- Yifei Cheng (ORCID: https://orcid.org/0000-0003-2894-9034)
- Meng Lv
- Xuefei Huang (ORCID: https://orcid.org/0000-0002-6468-5526)
- Jun Kong (ORCID: https://orcid.org/0000-0002-9398-8526)
- Yu‐Qian Sun
- Yu Wang
- Ning Wu
- Xiao‐Hui Zhang
- Xiao‐Dong Mo
- Lan‐Ping Xu
Institutions
- Peking University (CN)
- Peking University People's Hospital (CN)
- Center for Life Sciences (CN)
Publication Details
- Journal
- European Journal Of Haematology
- Published
- 2026-01-20
- DOI
- https://doi.org/10.1111/ejh.70108
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00